| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 6, 2003
From Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Med. Klinik IV (A.S., C.R., J.B., W.Z., M.T.), Berlin, and Severi-Med (R.R.), Muenster, Germany. * To whom correspondence should be addressed. E-mail: Tepel{at}zedat.fu-berlin.de.
Background--Increased oxidative stress, elevated plasma homocysteine concentration, increased pulse pressure, and impaired endothelial function constitute risk factors for increased mortality in patients with end-stage renal failure. Methods and Results--We investigated the metabolic and hemodynamic effects of intravenous administration of acetylcysteine, a thiol-containing antioxidant, during a hemodialysis session in a prospective, randomized, placebo-controlled crossover study in 20 patients with end-stage renal failure. Under control conditions, a hemodialysis session reduced plasma homocysteine concentration to 58±22% predialysis (mean±SD), whereas in the presence of acetylcysteine, the plasma homocysteine concentration was significantly more reduced to 12±7% predialysis (P<0.01). The reduction of plasma homocysteine concentration was significantly correlated with a reduction of pulse pressure. A 10% decrease in plasma homocysteine concentration was associated with a decrease of pulse pressure by 2.5 mm Hg. Analysis of the second derivative of photoplethysmogram waveform showed changes of arterial wave reflectance during hemodialysis in the presence of acetylcysteine, indicating improved endothelial function. Conclusions--Acetylcysteine-dependent increase of homocysteine removal during a hemodialysis session improves plasma homocysteine concentration, pulse pressure, and endothelial function in patients with end-stage renal failure.
Revised on October 10, 2003
Accepted on October 13, 2003
Acetylcysteine Reduces Plasma Homocysteine Concentration and Improves Pulse Pressure and Endothelial Function in Patients With End-Stage Renal Failure
Alexandra Scholze MD,
Related Article:
Circulation 2004 109: 294-295.
This article has been cited by other articles:
![]() |
T. M. Spormann, F. W. Albert, T. Rath, H. Dietrich, F. Will, J.-P. Stockis, G. Eisenbrand, and C. Janzowski Anthocyanin/Polyphenolic-Rich Fruit Juice Reduces Oxidative Cell Damage in an Intervention Study with Patients on Hemodialysis Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3372 - 3380. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Urquhart, D. J. Freeman, M. J. Cutler, R. Mainra, J. D. Spence, and A. A. House Mesna for Treatment of Hyperhomocysteinemia in Hemodialysis Patients: A Placebo-Controlled, Double-Blind, Randomized Trial Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1041 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Urquhart, D. J. Freeman, J. D. Spence, and A. A. House Mesna as a Nonvitamin Intervention to Lower Plasma Total Homocysteine Concentration: Implications for Assessment of the Homocysteine Theory of Atherosclerosis J. Clin. Pharmacol., August 1, 2007; 47(8): 991 - 997. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Spence Homocysteine: Call Off the Funeral Stroke, February 1, 2006; 37(2): 282 - 283. [Full Text] [PDF] |
||||
![]() |
C. Williams, B. A Kingwell, K. Burke, J. McPherson, and A. M Dart Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype Am. J. Clinical Nutrition, July 1, 2005; 82(1): 26 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Robinson Renal Disease, Homocysteine, and Cardiovascular Complications Circulation, January 27, 2004; 109(3): 294 - 295. [Full Text] [PDF] |
||||
![]() |
R. SoRelle Cardiovascular News Circulation, January 27, 2004; 109 (3): e9004 - e9005. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |